What You Should Know:
– Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed.
– The strategic collaboration will combine Accenture’s expertise in scaling AI solutions with 1910 Genetics’ innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies to patients.
1910 Genetics’ ITO™ Platform: Transforming Drug Discovery with AI
1910 Genetics’ proprietary Input-Transform-Output (ITO™) platform is a comprehensive AI solution designed to enhance the drug discovery process across various modalities and therapeutic areas. This multi-AI agent system leverages federated learning and diverse data streams to:
- Improve Target Identification: Identify promising drug targets with greater precision.
- Optimize Molecule Design: Design and optimize drug molecules for improved efficacy and safety.
- Conduct Advanced Simulations: Simulate drug interactions and predict clinical outcomes with greater accuracy.
By facilitating data-driven decision-making, the ITO™ platform increases the probability of clinical trial success, shortens development timelines, and reduces the overall cost of drug discovery.
Accenture’s Expertise in Scaling AI Solutions
Accenture’s deep understanding of AI implementation and scaling will be instrumental in helping biopharmaceutical companies seamlessly integrate 1910 Genetics’ AI platform into their existing drug development pipelines. This collaboration will enable companies to:
- Accelerate Drug Development: Bring new therapies to market faster by leveraging AI-powered insights.
- Reduce Costs: Optimize R&D processes and reduce expenses associated with traditional drug discovery methods.
- Improve Patient Outcomes: Develop more effective and affordable therapies for a wider range of diseases.
“In our discussions with biopharma companies, the desire for AI transformation of their traditional R&D processes is evident,” said Jen Nwankwo, PhD, founder and CEO of 1910 Genetics. “It’s also clear that 1910’s end-to-end AI platform—from in silico to the wet lab and back—addresses the challenges that biopharma companies face with point solutions. By collaborating with Accenture, we aim to bring 1910’s AI platform to biopharma companies as an enterprise-wide horizontal infrastructure that breaks down barriers in data, model, and computing power to accelerate the discovery and development of both small and large molecule therapeutics across all therapeutic areas.”
